AV 101

Drug Profile

AV 101

Alternative Names: 4-Chlorokynurenine - VistaGen; 4-CL-KYN; 7-Cl-KYNA; AV-101; L-4-chlorokynurenine; L-4-CI-KYN

Latest Information Update: 29 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Artemis Neuroscience
  • Developer National Institute of Mental Health; VistaGen Therapeutics
  • Class Analgesics; Antidepressants; Antiepileptic drugs; Antiparkinsonians; Neuroprotectants; Small molecules
  • Mechanism of Action NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Major depressive disorder
  • Phase I Epilepsy; Neuropathic pain; Parkinson's disease
  • Research Huntington's disease; Neurological disorders

Most Recent Events

  • 28 Sep 2017 VistaGen has patent protection for methods of production of AV 101 in China before September 2017
  • 28 Sep 2017 VistaGen receives patent allowance for methods of production of AV 101 in USA
  • 14 Aug 2017 VistaGen Therapeutics anticipates receiving fast track designation from the US FDA for AV 101 in Major depressive disorder (Adjunctive treatment) in the second half of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top